drugset / Trial / NCT01501695

Phase III Study of 5LGr to Treat Tic Disorder

NCT01501695

Phase 3 Completed 603 enrolled Tasly Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.

Timeline

Start
2008-01
Primary completion
2010-11
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject 5LGr Traditional medicine (herbal / TCM) 5 g
Subject 5LGr Traditional medicine (herbal / TCM) 7.5 g
Comparator Tiapride Small molecule 100 mg
Comparator Tiapride Small molecule 200 mg